Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors:

Robert Wesolowski,Neelesh Sharma,Laura Reebel,Mary Beth Rodal,Alexandra Peck,Brian L. West,Adhirai Marimuthu,Paul Severson,David A. Karlin,Afshin Dowlati,Mai H. Le,Lisa M. Coussens,Hope S. Rugo

Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors:

2019

Robert Wesolowski
Neelesh Sharma
Laura Reebel
Mary Beth Rodal
Alexandra Peck
Brian L. West
Adhirai Marimuthu
Paul Severson
David A. Karlin
Afshin Dowlati
Mai H. Le
Lisa M. Coussens
Hope S. Rugo

Purpose:To evaluate the safety, recommended phase II dose (RP2D) and efficacy of pexidartinib, a colony stimulating factor receptor 1 (CSF-1R) inhibitor, in combination with weekly paclitaxel in pa...

Keywords:

Pharmacology
Colony-stimulating factor
Pexidartinib
Paclitaxel
Medicine
phase i trials
in patient
weekly paclitaxel

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations